| Gt Target Gene: | CD19 |
| Tradename: | Aucatzyl |
| Dailymedid: | Obecabtagene autoleucel |
| Routes Of Administration: | Intravenous infusion |
| Atc Prefix: | None |
| Legal Us: | Rx-only |
| Legal Us Comment: | [1] |
| Drugbank: | DB17362 |
| Unii: | 760HJB0YRD |
Obecabtagene autoleucel, sold under the brand name Aucatzyl, is an anti-cancer medication used for the treatment of acute lymphoblastic leukemia. It is a CD19-directed genetically modified autologous T-cell immunotherapy.
The most common side effects include cytokine release syndrome, infections-pathogen unspecified, musculoskeletal pain, viral infections, fever, nausea, bacterial infectious disorders, diarrhea, febrile neutropenia, immune effector cell-associated neurotoxicity syndrome, hypotension, pain, fatigue, headache, encephalopathy, and hemorrhage.
Obecabtagene autoleucel was approved for medical use in the United States in November 2024.[2] [3]
Obecabtagene autoleucel is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
The US Food and Drug Administration (FDA) approved prescribing information for obecabtagene autoleucel has a boxed warning for cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and T-cell malignancies.
The most common side effects include cytokine release syndrome, infections-pathogen unspecified, musculoskeletal pain, viral infections, fever, nausea, bacterial infectious disorders, diarrhea, febrile neutropenia, immune effector cell-associated neurotoxicity syndrome, hypotension, pain, fatigue, headache, encephalopathy, and hemorrhage.
Efficacy was evaluated in FELIX (NCT04404660), an open-label, multicenter, single-arm trial that enrolled adults with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia. Enrolled participants were required to have relapsed following a remission lasting twelve months or less, relapsed or refractory acute lymphoblastic leukemia following two or more prior lines of systemic therapy, or disease that was relapsed or refractory three or more months after allogeneic stem cell transplantation.[4]
The major efficacy outcome measures were rate and duration of complete remission achieved within three months after infusion. Additional outcome measures were rate and duration of overall complete remission which includes complete remission and complete remission with incomplete hematologic recovery, at any time. Of the 65 participants evaluable for efficacy, 27 participants (42%; 95% confidence interval [CI]: 29%, 54%) achieved complete remission within three months. The median duration of complete remission achieved within three months was 14.1 months (95% CI: 6.1, not reached).
The US Food and Drug Administration (FDA) granted the application for obecabtagene autoleucel regenerative medicine advanced therapy (RMAT) and orphan drug designations.
Obecabtagene autoleucel was approved for medical use in the United States in November 2024.
Obecabtagene autoleucel is the international nonproprietary name.[5]
It is sold under the brand name Aucatzyl.